International Journal of Epidemiology

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (174) Request Permissions Google Scholar Articles by RODRIGUES, L. C Articles by WHEELER, J. G Search for Related Content PubMed PubMed Citation Articles by RODRIGUES, L. C Articles by WHEELER, J. G Social Bookmarking          What's this?

© 1993 Oxford University Press

other

Protective Effect of BCG against Tuberculous Meningitis and Miliary Tuberculosis: A Meta-Analysis

LAURA C RODRIGUES^*, VINOD K DIWAN and JEREMY G WHEELER^*

^* Epidemiology and Population Sciences, London School of Hygiene and Tropical Medicine Keppel Street, London WCIE 7HT, UK
Department of International Health Care Research, Karolinska Institutet Stockholm, Sweden

The protective effect of BCG against tuberculosis (TB) estimated in randomized controlled trials and observational studies ranges from negative to dose to a 100%. One of the many explanations offered for this is that different immunological mechanisms may be associated with protective effect against different forms and sites of disease. In this investigation, we recalculated vaccine protective effect separately for pulmonary disease and for meningeal/miliary disease in randomized controlled trials and case-control studies, tested for heterogeneity in site-specific estimates of protective effect and calculated a summary measure when appropriate. We found protective effect against pulmonary disease to be heterogenous to a statistically significant degree, and thus we did not calculate a summary measure of protection. Protective effect against meningeal and miliary TB was higher than against pulmonary disease and, except for a single study with two cases only, appeared to be homogeneous. Summary BCG protective effect against miliary or meningeal TB in randomized controlled trials was 86% (95% confidence interval [Cl] 65, 95) and in case-control studies 75% (95% Cl: 61, 84). The fact that protective effect appeared to be homogeneous against meningitis and miliary TB but not against pulmonary disease may result from the fact that patients with meningitis are on average younger and thus less likely to have been exposed to atypical bacteria; to a waning of the protective effect of BCG; or from the diversity of mechanisms of pathogenesis of pulmonary disease, which can originate from reinfection, reactivation or primary progression.

Received 1 April 1993

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				M. S. Rezai, G. Khotaei, S. Mamishi, M. Kheirkhah, and N. Parvaneh Disseminated Bacillus Calmette-Guerin Infection after BCG Vaccination J Trop Pediatr, July 1, 2008; (2008) fmn053v1. [Abstract] [Full Text] [PDF]

				D. J. C. Miles, M. van der Sande, S. Crozier, O. Ojuola, M. S. Palmero, M. Sanneh, E. S. Touray, S. Rowland-Jones, H. Whittle, M. Ota, et al. Effects of Antenatal and Postnatal Environments on CD4 T-Cell Responses to Mycobacterium bovis BCG in Healthy Infants in The Gambia Clin. Vaccine Immunol., June 1, 2008; 15(6): 995 - 1002. [Abstract] [Full Text] [PDF]

				R. B. Rock, M. Olin, C. A. Baker, T. W. Molitor, and P. K. Peterson Central Nervous System Tuberculosis: Pathogenesis and Clinical Aspects Clin. Microbiol. Rev., April 1, 2008; 21(2): 243 - 261. [Abstract] [Full Text] [PDF]

				A. M. Hebert, S. Talarico, D. Yang, R. Durmaz, C. F. Marrs, L. Zhang, B. Foxman, and Z. Yang DNA Polymorphisms in the pepA and PPE18 Genes among Clinical Strains of Mycobacterium tuberculosis: Implications for Vaccine Efficacy Infect. Immun., December 1, 2007; 75(12): 5798 - 5805. [Abstract] [Full Text] [PDF]

				T. R. Sterling, T. Martire, A. S. de Almeida, L. Ding, D. E. Greenberg, L. A. Moreira, H. Elloumi, A. P.V. Torres, C. C. Sant'Anna, E. Calazans, et al. Immune Function in Young Children With Previous Pulmonary or Miliary/Meningeal Tuberculosis and Impact of BCG Vaccination Pediatrics, October 1, 2007; 120(4): e912 - e921. [Abstract] [Full Text] [PDF]

				M A Anjay and P Anoop Tuberculous meningitis: more evidence for protective effect of BCG Arch. Dis. Child., March 1, 2007; 92(3): 277 - 277. [Full Text] [PDF]

				B Fathoala, M R Evans, I A Campbell, J Sastry, and M Alfaham Active surveillance for tuberculosis in Wales: 1996-2003 Arch. Dis. Child., November 1, 2006; 91(11): 900 - 904. [Abstract] [Full Text] [PDF]

				V Walker, G Selby, and I Wacogne Does neonatal BCG vaccination protect against tuberculous meningitis? Arch. Dis. Child., September 1, 2006; 91(9): 789 - 791. [Full Text] [PDF]

				C. C. WHALEN, A. CHIUNDA, S. ZALWANGO, L. NSHUTI, E. JONES-LOPEZ, A. OKWERA, C. HIRSCH, P. PETERS, W. H. BOOM, and R. D. MUGERWA IMMUNE CORRELATES OF ACUTE MYCOBACTERIUM TUBERCULOSIS INFECTION IN HOUSEHOLD CONTACTS IN KAMPALA, UGANDA. Am J Trop Med Hyg, July 1, 2006; 75(1): 55 - 61. [Abstract] [Full Text] [PDF]

				S S S Teo and D V Shingadia Does BCG have a role in tuberculosis control and prevention in the United Kingdom? Arch. Dis. Child., June 1, 2006; 91(6): 529 - 531. [Abstract] [Full Text] [PDF]

				L. Tsenova, R. Harbacheuski, A. L. Moreira, E. Ellison, W. Dalemans, M. R. Alderson, B. Mathema, S. G. Reed, Y. A. W. Skeiky, and G. Kaplan Evaluation of the Mtb72F Polyprotein Vaccine in a Rabbit Model of Tuberculous Meningitis Infect. Immun., April 1, 2006; 74(4): 2392 - 2401. [Abstract] [Full Text] [PDF]

				N. P. Shah, A. Singhal, A. Jain, P. Kumar, S. S. Uppal, M. V. P. Srivatsava, and H. K. Prasad Occurrence of Overlooked Zoonotic Tuberculosis: Detection of Mycobacterium bovis in Human Cerebrospinal Fluid J. Clin. Microbiol., April 1, 2006; 44(4): 1352 - 1358. [Abstract] [Full Text] [PDF]

				M. A. Horwitz, G. Harth, B. J. Dillon, and S. Maslesa-Galic Enhancing the Protective Efficacy of Mycobacterium bovis BCG Vaccination against Tuberculosis by Boosting with the Mycobacterium tuberculosis Major Secretory Protein Infect. Immun., August 1, 2005; 73(8): 4676 - 4683. [Abstract] [Full Text] [PDF]

				C. C. Whalen Diagnosis of Latent Tuberculosis Infection: Measure for Measure JAMA, June 8, 2005; 293(22): 2785 - 2787. [Full Text] [PDF]

				A. Martino, A. Sacchi, N. Sanarico, F. Spadaro, C. Ramoni, A. Ciaramella, L. P. Pucillo, V. Colizzi, and S. Vendetti Dendritic cells derived from BCG-infected precursors induce Th2-like immune response J. Leukoc. Biol., October 1, 2004; 76(4): 827 - 834. [Abstract] [Full Text] [PDF]

				N. E. Aronson, M. Santosham, G. W. Comstock, R. S. Howard, L. H. Moulton, E. R. Rhoades, and L. H. Harrison Long-term Efficacy of BCG Vaccine in American Indians and Alaska Natives: A 60-Year Follow-up Study JAMA, May 5, 2004; 291(17): 2086 - 2091. [Abstract] [Full Text] [PDF]

				D. A. Drevets, P. J. M. Leenen, and R. A. Greenfield Invasion of the Central Nervous System by Intracellular Bacteria Clin. Microbiol. Rev., April 1, 2004; 17(2): 323 - 347. [Abstract] [Full Text] [PDF]

				D. Guwatudde, M. Nakakeeto, E. C. Jones-Lopez, A. Maganda, A. Chiunda, R. D. Mugerwa, J. J. Ellner, G. Bukenya, and C. C. Whalen Tuberculosis in Household Contacts of Infectious Cases in Kampala, Uganda Am. J. Epidemiol., November 1, 2003; 158(9): 887 - 898. [Abstract] [Full Text] [PDF]

				J. Jason, L. K. Archibald, O. C. Nwanyanwu, P. N. Kazembe, J. A. Chatt, E. Norton, H. Dobbie, and W. R. Jarvis Clinical and Immune Impact of Mycobacterium bovis BCG Vaccination Scarring Infect. Immun., November 1, 2002; 70(11): 6188 - 6195. [Abstract] [Full Text] [PDF]

				BCG, TB and the UK DTB, October 1, 2002; 40(10): 78 - 80. [Abstract] [Full Text] [PDF]

				M. A. Chambers, A. Williams, G. Hatch, D. Gavier-Widen, G. Hall, K. Huygen, D. Lowrie, P. D. Marsh, and R. G. Hewinson Vaccination of Guinea Pigs with DNA Encoding the Mycobacterial Antigen MPB83 Influences Pulmonary Pathology but Not Hematogenous Spread following Aerogenic Infection with Mycobacterium bovis Infect. Immun., April 1, 2002; 70(4): 2159 - 2165. [Abstract] [Full Text] [PDF]

				Y. Shen, D. Zhou, L. Qiu, X. Lai, M. Simon, L. Shen, Z. Kou, Q. Wang, L. Jiang, J. Estep, et al. Adaptive Immune Response of Vgamma 2Vdelta 2+ T Cells During Mycobacterial Infections Science, March 22, 2002; 295(5563): 2255 - 2258. [Abstract] [Full Text] [PDF]

				B. G. Marshall, A. Wangoo, P. O'Gaora, H. T. Cook, R. J. Shaw, and D. B. Young Enhanced Antimycobacterial Response to Recombinant Mycobacterium bovis BCG Expressing Latency-Associated Peptide Infect. Immun., November 1, 2001; 69(11): 6676 - 6682. [Abstract] [Full Text] [PDF]

				A. Tanghe, J. Content, J.-P. Van Vooren, F. Portaels, and K. Huygen Protective Efficacy of a DNA Vaccine Encoding Antigen 85A from Mycobacterium bovis BCG against Buruli Ulcer Infect. Immun., September 1, 2001; 69(9): 5403 - 5411. [Abstract] [Full Text] [PDF]

				J. M Watson and F. Moss TB in Leicester: out of control, or just one of those things? BMJ, May 12, 2001; 322(7295): 1133 - 1134. [Full Text]

				M. Rahman, M. Sekimoto, I. Takamatsu, K. Hira, T. Shimbo, K. Toyoshima, and T. Fukui Economic evaluation of universal BCG vaccination of Japanese infants Int. J. Epidemiol., April 1, 2001; 30(2): 380 - 385. [Abstract] [Full Text] [PDF]

				I. Kristensen, P. Aaby, H. Jensen, and P. Fine Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa Commentary: an unexpected finding that needs confirmation or rejection BMJ, December 9, 2000; 321(7274): 1435 - 1435. [Abstract] [Full Text]

				M. P. Arbelaez, K. E Nelson, and A. Munoz BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection Int. J. Epidemiol., December 1, 2000; 29(6): 1085 - 1091. [Abstract] [Full Text] [PDF]

				M. A. Horwitz, G. Harth, B. J. Dillon, and S. Masle Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model PNAS, November 22, 2000; (2000) 250480397. [Abstract] [Full Text]

				Joint Tuberculosis Committee of the British Thorac Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000 Thorax, November 1, 2000; 55(11): 887 - 901. [Abstract] [Full Text]

				D. Menzies, T. N. Tannenbaum, and J. M. FitzGerald Tuberculosis: 10. Prevention Can. Med. Assoc. J., September 1, 1999; 161(6): 717 - 724. [Full Text] [PDF]

				M. A. Horwitz, G. Harth, B. J. Dillon, and S. Maslesa-Galic' Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model PNAS, December 5, 2000; 97(25): 13853 - 13858. [Abstract] [Full Text] [PDF]

Online ISSN 1464-3685 - Print ISSN 0300-5771

Copyright © 2008 International Epidemiological Association

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics